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Abstract
Vaginal infections caused by bacteria, Candida and Trichomonas vaginalis, affect millions of women annually worldwide. 
Symptoms and signs have limited value in differential diagnosis of three causes of vaginitis. Current laboratory methods 
for differential diagnosis are either expensive or time consuming. Therefore, in this work, development of a method based 
on gold nanoparticles has been investigated for rapid diagnosis of vaginal infections. Specific antibodies against three main 
causes of vaginal infections were raised in rabbits. The antibodies were then purified and conjugated to gold nanoparti-
cles and used in an agglutination test for detection of vaginal infections. Finally, sensitivity and specificity of this test for 
diagnosis of vaginal infections were estimated using culture method as gold standard. Purification of antibodies from sera 
was confirmed by electrophoresis. Construction of nanoparticles was proved by TEM and FT-IR methods. Conjugation of 
antibodies to gold nanoparticles was confirmed using XPS method. Sensitivity and specificity of gold nanoparticles for 
diagnosis of Candida species were 100%, for Gardnerella were 100% and 93%, and for T. vaginalis was 53.3% and 100%, 
respectively. Gold nanoparticle-based method is a simple, rapid, accurate, and cost-effective test for differential laboratory 
diagnosis of vaginal infections.
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Introduction
Vaginal infections affect millions of women annually world-
wide [1]. The most common causes of vaginitis are bacte-
rial vaginosis, vulvovaginal candidiasis, and trichomonia-
sis. Dysbacteriosis is implicated in 40–50%, vulvovaginal 
candidiasis in 20–25%, and trichomoniasis in 15–20% of 
cases [2]. Discharge is one of the most frequent gynecologic 
complaints. In the United States, vaginal infection account 
for more than 7% of patient visits to gynecologists’ clinics 
[3, 4]. These infections are associated with several adverse 
health outcomes, such as preterm birth or delivery of a low-
birth weight infant [1, 5, 6].
Dysbacteriosis (bacterial vaginosis) is a common condi-
tion, affecting many women annually [7, 8], and is associ-
ated with numerous health problems including preterm labor 
resulting in low-birth weight [9], pelvic inflammatory dis-
ease [10], and acquisition of the human immunodeficiency 
virus [11]. Malodorous vaginal discharge may be the only 
symptom of bacterial vaginosis, and many affected women 
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are asymptomatic [12]. In women with bacterial vaginitis, 
the concentration of anaerobic, Gardnerella vaginalis [13] 
and Mycoplasma hominis [14], is 100–1000 times higher 
than in normal women. However, these species are also 
found in subjects who do not have bacterial vaginosis and 
thus are not specific markers for disease [1].
Numerous studies have shown an association between 
bacterial vaginitis and adverse sequalae [15]. A meta-anal-
ysis investigation confirmed that bacterial vaginitis in preg-
nancy was associated consistently and significantly with an 
increased risk of prematurity [14].
Trichomonas vaginalis infection is a common sexually 
transmitted protozoal infection, with an estimated 180 mil-
lion prevalent cases worldwide [16]. The diagnosis of T. 
vaginalis infection in women is often made by microscopic 
examination (wet mount) of a vaginal fluid specimen or by 
an incidental finding on a Papanicolaou test report. The sen-
sitivity for these tests may be as low as 50% [17]. Other 
diagnostic options include culture and a DNA probe test, 
both of which have moderately higher sensitivity [18]. How-
ever, these options are not used routinely and are not cost 
effective for many clinicians.
Candida vaginitis is one of the most frequent infections 
of the female genital tract with a high incidence. Approxi-
mately 75% of sexually active women suffer at least one 
episode of Candida vaginitis and 10% of them have recurrent 
episodes [19]. Positive vaginal cultures for Candida species 
can be found in almost 15% of non-pregnant and 30% of 
pregnant women [20]. Among women with acute vulvovagi-
nal candidiasis, Candida albicans accounts for 80–90% of 
the isolated fungal species, whereas other species are less 
frequent [21].
Patients with vaginal infection frequently continue to have 
symptoms following treatment. The main cause of this treat-
ment failure is diagnostic errors. Many attempts have been 
made so far to determine the relationship between clinical 
criteria (symptoms and signs) and three causes of vaginitis 
(T. vaginalis, Candida species, and G. vaginalis). However, 
it is difficult to prove the etiology of vaginitis according to 
clinical criteria. It has been shown that symptoms are not 
differed among the three infections, and lack of vaginal odor 
in yeast infection is the only significantly different physical 
sign [20]. Therefore, it can be concluded that presenting 
symptoms and signs in vaginitis evaluation have limited 
value for differential diagnosis of vaginal infections [22].
In differential diagnosis of vaginal infections, laboratory 
diagnostic of vaginal infection is necessary for appropriate 
treatment and follow-up [23]. The laboratory diagnosis of 
vaginal infection in women is often made by microscopic 
examination (wet mount) of a vaginal fluid specimen. How-
ever, the sensitivity for these tests may be as low as 50% 
[24]. Other options for differential diagnosis of vaginal 
infections are culture and a DNA probe tests. These tests 
are more sensitive than wet smear method [25]. However, 
they are not used routinely, because they are time-consuming 
methods and they are not cost effective. To develop a rapid, 
sensitive and cost-effective method for simultaneous diagno-
sis of vaginal infections, in this work, differential diagnosis 
of these infections by gold nanoparticles coated with specific 
antibodies has been investigated.
Materials and methods
In this work, vaginal swabs were collected from 635 women 
with vaginal symptoms referred to gynecology clinics in 
Chaharmahal va Bakhtiari province of Iran in 2017. In the 
first step of this research, an agglutination test using gold 
nanoparticles coated with specific antibodies was developed 
for differential diagnosis of vaginal infections and in the sec-
ond step sensitivity and specificity of the test was estimated.
Development of a gold nanoparticle‑based method 
for differential diagnosis of vaginal infections
Antigen preparation
With informed consent, vaginal samples were collected 
from women referred to gynecology clinics. The samples 
were then cultured in appropriate mediums for each micro-
organism. Colombia agar medium, Sabra dextrose agar, 
and TYSI33 mediums were used for culturing G. vaginalis, 
Candida spp., and T. vaginalis, respectively. After growth 
in culture medium and performance of appropriate tests to 
confirm the infections, the above three agents were trans-
ferred to three individual tubes containing PBS. The micro-
organisms were then given three washes with PBS to remove 
constituent of the culture media. After that, the organisms 
were sonicated to prepare crude antigens. In case of Candida 
spp., species determination was not considered.
Preparation of specific antibodies
The prepared crude antigens along with adjuvant were 
injected to individual rabbits to raise poly-specific antisera. 
Complete Freunds’ adjuvant was used for the first injection 
and incomplete one for the boosters. Following the third 
booster, a blood sample was prepared from all rabbits and 
presence of specific antibodies against causing agents of 
vaginal infection was checked using ELISA method, as we 
published before [26]. With the presence of appropriate level 
of specific antibodies, the rabbits were bled out and their 
sera was kept at − 20 °C until used. Antibodies in the sera 
were purified using salting out method. Antibody purifica-
tion was then confirmed by electrophoresis method (sebia 
Capillarys 2 Flexiercing-France).
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Preparation of gold nanoparticles and conjugation 
with specific antibodies
Gold nanoparticles with pendent carboxylic and alcohol 
functional groups were prepared [27] and then conjugated 
to specific antibodies against Candida species, T. vaginalis 
or Gardnerella species [28]. Briefly, the gold nanoparticles 
were synthesized using Laaksonen et al.’s method [27] with 
slight modification. To 200 mL of ethanol solution contain-
ing 2.7 mmol 0.3 mmol 16-mercaptohexadecanoic acid, 
6 mL of a solution containing  HAuCl4·3H2O (410 mg) in 
water (6 mL) was added. The solution was then cooled to 
0 °C, and then, 20 mL of a freshly prepared aqueous solu-
tion containing 380 mg of NaBH4 was added. The resulting 
solution containing capped Au nanoparticles with pendant 
carboxylic acid functional groups was stirred for 3 h, and 
then, the material was allowed to precipitate to the bottom 
of the flask. The particles were then washed and dried under 
vacuum for 10 h and were examined using transmission elec-
tron microscopy (TEM) (Philips CM30, The Netherlands) 
and the FT-IR spectrum was obtained on a FT-IR spectrom-
eter (6300-Jasco-Japan). The prepared gold nanoparticles 
functionalized with 16-mercaptohexadecanoic acid and 
were conjugated to the antibodies according to the method 
reported by Zhao et al. [29]. For this purpose, 100 mg of 
Au nanoparticles with pendant carboxylic acid functional 
groups, and 2  mg of antibody was added to a solution 
containing 0.25 g (1.3 mmol) 1-ethyl-3-3(3-dimethylami-
nopropyl) carbodiimide hydrochloride (EDC) and 0.25 g 
(2.2 mmol) N-hydroxysuccinimide in 5 mL 0.01 PBS (pH 
7.4), and stirred at room temperature for 0.5 h. Material 
was then washed with 0.01 PBS. The obtained material was 
then characterized using µX-ray photoelectron spectroscopy 
(XPS) (PHI-5400, Physical Electronics USA).
Reaction of gold nanoparticles conjugated 
antibodies with the related antigens
On an agglutination slide, one drop (50 µL) of gold nano-
particles conjugated with anti-Candida antibodies was mixed 
with one drop (50 µL) of PBS containing 1 × 106 Candida 
cells/mL. With occurrence of agglutination, the test con-
sidered positive. This test was also repeated for T. vaginalis 
and G. vaginalis.
Determination of sensitivity and specificity of gold 
nanoparticles’ method
Study population was women with signs and symptoms of 
vaginal infections referred to gynecology clinics in Chaha-
rmahal va Bakhtiari province of Iran in 2017. With informed 
consent from each patient, five vaginal swabs were taken and 
used as follows.
The first swab was used for microscopic examination (wet 
smear). The second, third, and fourth swabs were used for 
specific culture medium for T. vaginalis, Candida spp., or 
G. vaginalis, respectively. The fifth swab kept at − 20 to 
be tested with gold nanoparticles’ method. Sampling was 
continued until at least 30 positive samples of T. vaginalis, 
Candida spp. or G. vaginalis were collected. After that the 
developed gold nanoparticles method was used to examine 
the fifth swab. For this purpose, the swabs were shacked 
in 500 µL normal saline, then three drops (50 µL) of it put 
on agglutination slides on different spots. A drop (50 µL) 
of nanoparticles coated with anti T. vaginalis, anti-Candida 
spp. or anti G. vaginalis was added to drops 1–3, respec-
tively, and shake for several seconds. With the formation 
of agglutination, the test considered to be positive. Finally, 
the results of nanoparticles’ method were compared with 
the results of culture methods (gold standard) to estimate 
sensitivity and specificity of the newly developed nanopar-
ticles test.
Analytical sensitivity and specificity of the gold 
nanoparticles method in detection of Candida spp. 
and G. vaginalis
For sensitivity, 0.5 McFarland standards were made for 
Candida spp. and G. vaginalis and different dilutions of the 
them were prepared and each dilution was then tested by 
gold nanoparticles method. For specificity gold nanopar-
ticles, method was used for detection of Escherichia coli, 




Gold nanoparticle was made and tested using transmission 
electron microscopy (TEM) and Fourier transform infrared 
spectroscopy (FTIR) (Figs. 1, 2).
Conjugation of gold nanoparticles with specific 
antibodies against Trichomonas vaginalis, Candida 
spp., or Gardnerella vaginalis
Three antisera raised against T. vaginalis, Candida spp., 
and G. vaginalis subjected to salting out method to purify 
the antibodies. As shown in Fig. 3, antibodies were par-
tially purified. In the next step, gold nanoparticles were 
conjugated with the three specific antibodies. Conjugated 
of the gold nanoparticles with each specific antibody was 
confirmed using X-ray photoelectron spectroscopy (XPS) 
method (Fig. 4).
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Reaction of gold nanoparticles conjugated antibodies 
with vaginal infections agents
One drop (50 µL) of gold nanoparticles conjugated with anti-
Candida antibodies was mixed with one drop (50 µL) of PBS 
containing Candida. As control, one drop (50 µL) of PBS 
alone was mixed with conjugated nanoparticles. In addition, 
one drop (50 µL) of vaginal samples was mixed with the con-
jugated nanoparticles. As shown in Fig. 5, after few seconds, a 
strong agglutination was observed. This test was also repeated 
for T. vaginalis and G. vaginalis.
Examination of the vaginal samples using wet 
smear, culture, and antibody‑conjugated gold 
nanoparticles
635 vaginal samples were examined using wet smear and 
culture methods to detect 30 positive samples for T. vagi-
nalis, Candida spp., and G. vaginalis, and then, the devel-
oped nanoparticles’ method was performed on 90 posi-
tive samples (30 for each vaginal agent) and 90 negative 
samples. The results of this examination are summarized 
in Table 1.
Fig. 1  TEM of prepared gold 
nanoparticles
Fig. 2  FT-IR spectrum of functionalized gold nanoparticles with 
carboxylic acid groups. Peaks at various ranges related to differ-
ent stretching and bending modes of the functional groups. Peaks 
at 3049.87  cm−1 are ascribed to C–H stretching of the alkyl groups 
and the peak at 1496.49 to the C–H deformation of the alkyl group. 
The peak at 1580.38  cm−1 is related to stretching of the carboxylic 
group. The peak at 1266.04  cm−1 corresponding to O–H bending 
was observed. A peak at 813.813 cm−1 is also present. The peak at 
1130.08  cm−1 is characteristic of the out-of-plane O–H-bending 
mode and the peak at 3429.78 cm−1 is due to O–H stretching
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Sensitivity and specificity of gold nanoparticle 
method for diagnosis of vaginal infections
Sensitivity and specificity of gold nanoparticle method for 
detection of T. vaginalis, Candida spp., and G. vaginalis in 
vaginal samples were estimated. Gold nanoparticles’ method 
has a high level of both sensitivity and specificity for detection 
of Candida spp. and G. vaginalis. However, the sensitivity of 
the test for detection of T. vaginalis was 53.33%. More details 
about sensitivity and specificity of gold nanoparticles method 
are shown in Table 2.
Results of analytical sensitivity and specificity 
of the gold nanoparticles method in detection 
of Candida spp. and Gardnerella vaginalis
Gold nanoparticles’ method was able to detect as much as 25 
Candida cells in 1 ml (0.25 × 102 CFU/mL). The analytical 
sensitivity of the test for G. vaginalis was 1 × 102 CFU/mL. 
Therefore, low inoculum of the test for Candida and G. vagi-
nalis was 0.25 × 102 CFU/mL and 1 × 102 CFU/mL, respec-
tively. In analytical specificity, the gold nanoparticles’ method 
did not detect Escherichia coli, Klebsiella, Enterobacter aero-
genes, Rodotrolla spp., and Geotrichum sp.
Fig. 3  Electrophoresis of purified antibodies against Candida in comparison with electrophoresis of the normal sera
Fig. 4  X-ray photoelectron spectrum of gold nanoparticle with the 
attached antibody anti-Candida spp. This figure indicates the pres-
ence of the antibody on the nanoparticles by X-ray photoelectron 
spectroscopy (XPS). A peak at ~ 400, related to nitrogen present in 
the sample from antibody, is observed
Fig. 5  Agglutination between Candida (1), PBS (2), and a vaginal 
sample (3) and the gold nanoparticles conjugated with anti-Candida
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Discussion
To provide a rapid and accurate test for differential diag-
nosis of vaginal infections in human, in this work, a gold 
nanoparticle method was developed. The test was rapid, 
and after only few seconds, a strong agglutination is devel-
oping between antigen and the conjugated antibodies. 
Results of this investigation showed that gold nanoparticle 
method has a high level of sensitivity and specificity for 
detection of human vaginal infections caused by Candida 
spp. and G. vaginalis.
Itching was the only symptom more frequently noted 
among symptomatic patients [20]. In an investigation, it 
has been shown that the clinical diagnosis of vaginal infec-
tion is inadequate in diagnosis of causative agents of vagi-
nal infections and should be confirmed with an appropriate 
laboratory test [30]. Precision and accuracy of microscopy 
of vaginal fluid method are poor [31] and misdiagnosis 
creates stress for the patient, delays appropriate inter-
vention, and places a financial burden on the health care 
system. In an investigation, a nucleic-acid probe-based 
test was developed for differential diagnosis of vaginal 
infections. Sensitivity and specificity of more than 90% 
were reported for this test in detection of G. vaginalis, 
Candida spp., and T. vaginalis in vaginal specimens [32]. 
Although this test is both sensitive and specific, but it is 
an expensive method and needs special equipment to do 
the test. In another investigation, the sensitivity of clini-
cian microscopy for diagnosis of vulvovaginal candidiasis, 
vaginal trichomoniasis, and bacterial vaginosis was 39.6%, 
90.4%, and 75.0%, respectively, while the sensitivity of a 
DNA probe method was 75.0%, 95.7%, and 86.5%. The 
specificity of conventional and DNA probe method was 
96.6%, 76.5%, and 70.8%, and 98.5%, 95.4%, and 60.7%, 
respectively [33]. Daniel et al. showed that the sensitivity 
of wet mount diagnosis of trichomoniasis was 62%, and 
of Candida by microscopy was 22% [13]. They also con-
cluded that symptoms alone should not be used to direct 
treatment of vaginal infection [13].
In another work, it has been shown that molecular detec-
tion of G. vaginalis has similar sensitivity and specificity to 
Gram stain method [34]. Performance of molecular methods 
is time consuming and needs especial equipment.
Culture methods are used for diagnosis of G. vaginalis, 
Candida species, and T. vaginalis. This method is time con-
suming, and do not provide timely results. A DNA probe 
analysis of vaginal fluid for G. vaginalis, Candida spe-
cies, and T. vaginalis is sensitive and specific for detection 
of these agents [35]. However, DNA probe analysis is an 
expensive method and needs especial equipment.
Molecular methods have been used as complements to 
conventional methods and providing more accurate results 
in less time (1.5–3 h). Therefore, they are considered as 
accurate and quick tests for diagnosis of candidiasis. How-
ever, these tests are expensive and lack appropriate stand-
ardization [36]. Trama et al. developed a PCR-based method 
for diagnosis of Candida species in vaginal samples. They 
showed that this test provided high level of both sensitivity 
and specificity for diagnosis of vaginal candidiasis [37].
Sensitivity and specificity of 100% have been reported for 
PCR method in detection of T. vaginalis in vaginal samples 
[38]. In another work, it has been shown that vaginal swab 
ATV TMA was significantly more sensitive than wet mount 
or culture in detection of T. vaginalis in women, while in 
men urethral swab, ATV TMA was significantly more sen-
sitive than culture or PCR [39]. In another work, Lisa et al. 
showed that the sensitivity and specificity of PCR using 
vaginal samples for detection of T. vaginalis were 89 and 
97%, respectively [40]. It has been shown that PCR could 
Table 1  Comparison of results 
of wet smear, culture and 
Gold nanoparticles method 
for detection of Trichomonas 
vaginalis, Candida, and 
Gardnerella vaginalis 
Gardnerella vaginalis Candida spp. Trichomonas vaginalis
Positive Negative Positive Negative Positive Negative
Nano method
 Positive 30 2 30 0 16 0
 Negative 0 28 0 30 14 30
Total 30 30 30 30 30 30
Table 2  Sensitivity and 
specificity of gold nano 
method in detection of vaginal 
infections





Gardnerella vaginalis 100 93.3 93.75 100
Candida spp. 100 100 100 100
Trichomonas vaginalis 53.33 100 100 36.3
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be method of choice for detection of T. vaginalis in vaginal 
samples [41]. In another work, it has been reported that real-
time PCR assay is sensitive and specific for the detection of 
T. vaginalis DNA in vaginal samples [42]. In contrast lower 
sensitivity of PCR method for detection of T. vaginalis has 
been reported by Crucitti et al. [43].
Time, cost, and accuracy are important criteria of a 
laboratory test for detection of vaginal infections agents in 
clinical samples. In this investigation, we developed a quick, 
cost effective, and accurate test for laboratory differential 
diagnosis of vaginal infections simultaneously. Therefore, 
conventual and molecular methods which are either time 
consuming or expensive can be replaced by this test. Moreo-
ver, this method is easy to do with no need to any equipment 
and can also be performed in gynecological clinics.
Conclusion
Gold nanoparticle method developed in this work has a high 
level of specificity and sensitivity for detection of Candida 
and Gardernela spp. in vaginal samples. Simultaneous dif-
ferential diagnosis of vaginal infections simply and quickly 
is the most important advantages of this test.
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